A phase I study of the addition of high-dose lenalidomide to melphalan conditioning for autologous stem-cell transplant in relapsed or refractory multiple myeloma

Category Primary study
JournalClinical Lymphoma, Myeloma and Leukemia
Year 2015
This article has no abstract
Epistemonikos ID: 50d18b3cda75a2dceccbad03d82d073982bca452
First added on: Feb 07, 2025